Literature DB >> 21646627

Meta-analysis of the relationship between Parkinson disease and melanoma.

Rui Liu1, Xiang Gao, Yi Lu, Honglei Chen.   

Abstract

OBJECTIVE: To assess the epidemiologic evidence on melanoma in relation to Parkinson disease (PD) via systematic review and meta-analysis.
METHODS: Epidemiologic studies on melanoma and PD were searched using PubMed, Web of Science, Scoups, and Embase (1965 through June 2010). Eligible studies were those that reported risk estimates of melanoma among patients with PD or vice versa. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models.
RESULTS: We identified 12 eligible publications on melanoma and PD: 8 had fewer than 10 cases with both PD and melanoma, and 7 provided gender-specific results. The pooled OR was 2.11 (95% CI 1.26-3.54) overall, 2.04 (1.55-2.69) for men, and 1.52 (0.85-2.75) for women. Analyses by temporal relationship found that melanoma occurrence was significantly higher after the diagnosis of PD (OR 3.61, 95% CI 1.49-8.77), but not before PD diagnosis (OR 1.07, 95% CI 0.62-1.84). Further analyses revealed that the lack of significance in the latter analysis was due to one study, which when excluded resulted in a significant association (OR 1.44, 95% CI 1.06-1.96). We also analyzed nonmelanoma skin cancers in relation to PD and found no significant relationship (OR 1.11, 95% CI 0.94-1.30).
CONCLUSIONS: Collective epidemiologic evidence supports an association of PD with melanoma. Further research is needed to examine the nature and mechanisms of this relationship.
Copyright © 2011 by AAN Enterprises, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21646627      PMCID: PMC3116643          DOI: 10.1212/WNL.0b013e31821e554e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  Counterpoint: sunscreen use is a safe and effective approach to skin cancer prevention.

Authors:  Marianne Berwick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10       Impact factor: 4.254

2.  Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.

Authors:  John M Bertoni; John Philip Arlette; Hubert H Fernandez; Cheryl Fitzer-Attas; Karen Frei; Mohamed N Hassan; Stuart H Isaacson; Mark F Lew; Eric Molho; William G Ondo; Tania J Phillips; Carlos Singer; James P Sutton; John E Wolf
Journal:  Arch Neurol       Date:  2010-03

3.  Smoking duration, intensity, and risk of Parkinson disease.

Authors:  H Chen; X Huang; X Guo; R B Mailman; Y Park; F Kamel; D M Umbach; Q Xu; A Hollenbeck; A Schatzkin; A Blair
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

4.  Comorbid cancer in Parkinson's disease.

Authors:  Raymond Y Lo; Caroline M Tanner; Stephen K Van Den Eeden; Kathleen B Albers; Amethyst D Leimpeter; Lorene M Nelson
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

Review 5.  Parkinson's disease and cancer risk: a systematic review and meta-analysis.

Authors:  Archna Bajaj; Jane A Driver; Eva S Schernhammer
Journal:  Cancer Causes Control       Date:  2010-01-07       Impact factor: 2.506

6.  Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Authors:  Yasuhiro Matsuo; Tetsu Kamitani
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

7.  Pesticide use and cutaneous melanoma in pesticide applicators in the agricultural heath study.

Authors:  Leslie K Dennis; Charles F Lynch; Dale P Sandler; Michael C R Alavanja
Journal:  Environ Health Perspect       Date:  2010-02-17       Impact factor: 9.031

8.  Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease.

Authors:  Jane A Driver; Tobias Kurth; Julie E Buring; J Michael Gaziano; Giancarlo Logroscino
Journal:  Cancer Causes Control       Date:  2007-06-12       Impact factor: 2.506

9.  Treatment with levodopa and risk for malignant melanoma.

Authors:  Jørgen H Olsen; Karina Tangerud; Lene Wermuth; Kirsten Frederiksen; Søren Friis
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

10.  A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease.

Authors:  Jane A Driver; Giancarlo Logroscino; Julie E Buring; J Michael Gaziano; Tobias Kurth
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  60 in total

1.  Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease.

Authors:  Kathrine Rugbjerg; Søren Friis; Christina Funch Lassen; Beate Ritz; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2012-03-22       Impact factor: 7.396

2.  Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Authors:  Ilir Agalliu; Roberto A Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2019-07-26       Impact factor: 10.338

3.  The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.

Authors:  Xiqun Chen; Hongxiang Chen; Waijiao Cai; Michael Maguire; Bailiu Ya; Fuxing Zuo; Robert Logan; Hui Li; Katey Robinson; Charles R Vanderburg; Yang Yu; Yinsheng Wang; David E Fisher; Michael A Schwarzschild
Journal:  Ann Neurol       Date:  2017-01-23       Impact factor: 10.422

4.  Associations between cancer and Parkinson's disease in U.S. elderly adults.

Authors:  D Michal Freedman; Jincao Wu; Honglei Chen; Eric A Engels; Lindsey R Enewold; Neal D Freedman; James J Goedert; Ralph W Kuncl; Mitchell H Gail; Ruth M Pfeiffer
Journal:  Int J Epidemiol       Date:  2016-03-17       Impact factor: 7.196

5.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Authors:  Ilir Agalliu; Marta San Luciano; Anat Mirelman; Nir Giladi; Bjorg Waro; Jan Aasly; Rivka Inzelberg; Sharon Hassin-Baer; Eitan Friedman; Javier Ruiz-Martinez; Jose Felix Marti-Masso; Avi Orr-Urtreger; Susan Bressman; Rachel Saunders-Pullman
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

6.  No association between Parkinson disease alleles and the risk of melanoma.

Authors:  Shasha Meng; Fengju Song; Honglei Chen; Xiang Gao; Christopher I Amos; Jeffrey E Lee; Qingyi Wei; Abrar A Qureshi; Jiali Han
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-11-15       Impact factor: 4.254

7.  Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.

Authors:  Radu Constantinescu; Jordan Elm; Peggy Auinger; Saloni Sharma; Erika F Augustine; Laith Khadim; Karl Kieburtz
Journal:  Mov Disord       Date:  2013-12-03       Impact factor: 10.338

8.  Update on the Epidemiology of Melanoma.

Authors:  Steven T Chen; Alan C Geller; Hensin Tsao
Journal:  Curr Dermatol Rep       Date:  2013-03-01

9.  Abnormal differentiation of dopaminergic neurons in zebrafish trpm7 mutant larvae impairs development of the motor pattern.

Authors:  Amanda R Decker; Matthew S McNeill; Aaron M Lambert; Jeffrey D Overton; Yu-Chia Chen; Ramón A Lorca; Nicolas A Johnson; Susan E Brockerhoff; Durga P Mohapatra; Heather MacArthur; Pertti Panula; Mark A Masino; Loren W Runnels; Robert A Cornell
Journal:  Dev Biol       Date:  2013-11-27       Impact factor: 3.582

10.  The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder.

Authors:  Ziv Gan-Or; Noreen Mohsin; Simon L Girard; Jacques Y Montplaisir; Amirthagowri Ambalavanan; Stephanie Strong; Victoria Mallett; Sandra B Laurent; Cynthia V Bourassa; Michel Boivin; Melanie Langlois; Isabelle Arnulf; Birgit Högl; Birgit Frauscher; Christelle Monaca; Alex Desautels; Jean-François Gagnon; Ronald B Postuma; Patrick A Dion; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Guy A Rouleau
Journal:  Neurobiol Aging       Date:  2016-04-06       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.